Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 0 · 0%Moderate 1 · 33.3%High 0 · 0%

Betamethasone acetate plus phosphate vs betamethasone phosphate – fetal/neonatal outcomes

Chronic lung disease · women at risk of preterm birth

The review found no eligible studies for this question.

1 finding from 1 review

Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Betamethasone 12‐hourly vs 24‐hourly dosing – fetal/neonatal outcomes

Chronic lung disease · women at risk of preterm birth

It is very uncertain whether betamethasone 12‐hourly changes chronic lung disease compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).

1 finding from 1 review

Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
RR 0.77 [0.48, 1.24]
1 study · 253 participants
Very low

Dexamethasone vs betamethasone – child outcomes

Chronic lung disease · women at risk of preterm birth

Dexamethasone showed no clear difference in chronic lung disease compared with betamethasone – fetal/neonatal outcomes (moderate certainty).

1 finding from 1 review

Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes only
RR 0.92 [0.64, 1.34]
1 study · 1509 participants
Moderate